rs149694033
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_033305.3(VPS13A):c.5884C>T(p.Arg1962Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00495 in 1,613,306 control chromosomes in the GnomAD database, including 27 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_033305.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VPS13A | NM_033305.3 | c.5884C>T | p.Arg1962Cys | missense_variant | 45/72 | ENST00000360280.8 | NP_150648.2 | |
VPS13A | NM_001018037.2 | c.5767C>T | p.Arg1923Cys | missense_variant | 44/71 | NP_001018047.1 | ||
VPS13A | NM_015186.4 | c.5884C>T | p.Arg1962Cys | missense_variant | 45/69 | NP_056001.1 | ||
VPS13A | NM_001018038.3 | c.5884C>T | p.Arg1962Cys | missense_variant | 45/69 | NP_001018048.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VPS13A | ENST00000360280.8 | c.5884C>T | p.Arg1962Cys | missense_variant | 45/72 | 1 | NM_033305.3 | ENSP00000353422 | P4 |
Frequencies
GnomAD3 genomes AF: 0.00393 AC: 598AN: 152042Hom.: 3 Cov.: 32
GnomAD3 exomes AF: 0.00362 AC: 907AN: 250868Hom.: 3 AF XY: 0.00358 AC XY: 485AN XY: 135582
GnomAD4 exome AF: 0.00506 AC: 7394AN: 1461146Hom.: 24 Cov.: 30 AF XY: 0.00491 AC XY: 3566AN XY: 726856
GnomAD4 genome AF: 0.00392 AC: 597AN: 152160Hom.: 3 Cov.: 32 AF XY: 0.00383 AC XY: 285AN XY: 74378
ClinVar
Submissions by phenotype
not provided Benign:6
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 08, 2019 | - - |
Likely benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 11, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | VPS13A: BP4, BS2 - |
Chorea-acanthocytosis Uncertain:2Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. - |
Likely benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 15, 2019 | - - |
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 02, 2020 | - - |
not specified Benign:1
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
VPS13A-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 23, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at